Mean weight loss with semaglutide 2.4 mg
Over 68 weeks in the STEP-1 trial of 1,961 adults with overweight or obesity — vs. 2.4% with placebo.
STEP-1 · Wilding et al., NEJM 2021 ↗Starting at $149 · Free 1-2 Day Shipping · Cancel Anytime




GLP-1s Clinically Studied for Weight Management*
Not another 30-day fix. A medically-guided weight management program — GLP-1 treatment designed around your body, your goals, and your life. Starting at $149. No hidden fees.
Available in 39 U.S. states · Licensed providers in your state
Be the first to review us on Trustpilot*Up to 20.9% average body weight loss over 72 weeks with tirzepatide 15mg in the SURMOUNT-1 trial (Jastreboff et al., N Engl J Med 2022); up to 14.9% over 68 weeks with semaglutide 2.4mg in the STEP-1 trial (Wilding et al., N Engl J Med 2021). Results are from studies of FDA-approved branded medications and may not reflect outcomes with compounded formulations. Individual results vary; weight loss is not guaranteed.
GLP-1 research cited in our clinical protocols
AvataCore treatment protocols are informed by clinical data from peer-reviewed research.
AvataCore is not affiliated with these publications.
Avg. body weight reduction with semaglutide 2.4mg at 68 weeks1
Avg. body weight reduction with tirzepatide 15mg at 72 weeks2
Of STEP 1 participants lost ≥5% of body weight1
Licensed provider support via our clinical partner
1 Wilding et al., N Engl J Med 2021 (STEP 1) · 2 Jastreboff et al., N Engl J Med 2022 (SURMOUNT-1)
Individual results vary. Trial data does not guarantee outcomes.
Built for Clinical Trust
US-Licensed Providers
Board-certified MDs & NPs
HIPAA Compliant
End-to-end encryption
US-Based Pharmacy
State-licensed
HSA/FSA May Apply*
Use pre-tax dollars
30-Day Guarantee
Consultation refund if not prescribed
Three clinically-backed paths. Take our 60-second quiz and a licensed provider matches you to the right one.

Weekly injection for steady appetite control and reliable weight loss.
Starting at $149

Daily dissolvable tablet for patients who prefer not to inject.
Starting at $149

Dual-action weekly injection on two hormone pathways for more powerful results in some patients.
Starting at $199
*Eligibility required. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. See our Medication Options disclosure.
You’ve heard of these
AvataCore does not dispense these branded products. We use compounded medications prepared by 503A state-licensed pharmacies under USP <797> standards and overseen by a licensed clinician.

Starting at $1,579
Semaglutide · Daily tablet · Novo Nordisk
Wegovy® is a registered trademark of Novo Nordisk. Not sold by AvataCore.

Starting at $1,579
Semaglutide · Weekly injection · Novo Nordisk
Wegovy® is a registered trademark of Novo Nordisk. Not sold by AvataCore.

Starting at $1,249
Tirzepatide · Weekly injection · Eli Lilly
Mounjaro® is a registered trademark of Eli Lilly. Not sold by AvataCore.

Starting at $1,249
Tirzepatide · Weekly injection · Eli Lilly
Zepbound® is a registered trademark of Eli Lilly. Not sold by AvataCore.

Starting at $1,149
Semaglutide · Weekly injection · Novo Nordisk
Ozempic® is a registered trademark of Novo Nordisk. Not sold by AvataCore.
Brand-name medications shown for reference. AvataCore does not directly dispense Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Pricing reflects publicly available retail estimates and is subject to change. Compounded medications are different from FDA-approved branded products. AvataCore is not affiliated with Novo Nordisk or Eli Lilly.
Average body weight reduction reported in peer-reviewed GLP-1 trials
Trial data reflects FDA-approved branded formulations of semaglutide and tirzepatide. Compounded formulations are different from FDA-approved branded products and have not been evaluated by the FDA for safety, efficacy, or quality; outcomes with compounded preparations may differ. Individual results vary based on dose, adherence, diet, and other factors. Weight loss is not guaranteed. References: Wilding JPH et al., NEJM 384:989-1002 (2021); Jastreboff AM et al., NEJM 387:205-216 (2022).
Start your weight management journey today with AvataCore's easy, personalized process for accessing GLP-1 medications. Designed with your convenience in mind, our streamlined approach ensures you're supported every step of the way, from approval to receiving your prescription.

Complete a quick online evaluation to determine if GLP-1 medication is right for you. Our team of licensed professionals will review your information and provide approval in no time.

Once approved, you'll receive personalized care and a prescription to support your weight loss and health goals. Your care plan is designed to support your weight management journey under licensed-provider care.

Your medication will be shipped directly to your door for maximum convenience. With AvataCore, starting your treatment is as simple as opening your package and following our easy-to-use instructions.
Free to start · No credit card required


AvataCore provides 24/7 access to a dedicated team of specialists, ensuring you have the support you need around the clock. With unlimited appointments, messaging and support, you can confidently reach out for guidance, ask questions, or address concerns at any time.
Unlimited Messaging
Chat with your care team anytime
24/7 Availability
Support when you need it most
Dedicated Specialists
A team that knows your journey
No Extra Cost
All included in your plan
From Peer-Reviewed Research
Six findings from the pivotal GLP-1 trials that define how we build our care plans. No cherry-picked quotes — just the numbers from the peer-reviewed record.
Over 68 weeks in the STEP-1 trial of 1,961 adults with overweight or obesity — vs. 2.4% with placebo.
STEP-1 · Wilding et al., NEJM 2021 ↗Over 72 weeks in the SURMOUNT-1 trial of 2,539 adults — the highest reduction in any published GLP-1 study to date.
SURMOUNT-1 · Jastreboff et al., NEJM 2022 ↗Clinically meaningful weight reduction threshold reached by the vast majority of STEP-1 participants — the benchmark providers care about.
STEP-1 · Wilding et al., NEJM 2021 ↗Pooled GLP-1 trial arms showed 6× the weight reduction of placebo + lifestyle modification groups over the same duration.
STEP / SURMOUNT pooled control arms ↗Appetite, satiety, and metabolic set point are largely governed by hormones — not willpower. GLP-1 works with your biology, not against it.
Obesity is a chronic disease · AMA 2013 ↗Pivotal trials run 68–72 weeks. Weight loss continues throughout — which is why our care plans are built for the long arc, not 30 days.
STEP-1 · SURMOUNT-1 ↗Trial data reflects FDA-approved branded formulations. Compounded preparations are different from FDA-approved branded products and have not been evaluated by the FDA for safety, efficacy, or quality; outcomes may differ. Individual results vary. Weight loss is not guaranteed.
The AvataCore Guarantee
If you're not satisfied with your initial provider consultation experience, we'll refund the consultation fee. Your treatment plan is determined by your licensed provider based on your medical history.
We only charge for care you can actually receive. Your trust is our top priority — from consultation to your door.

If you are not a candidate for GLP-1 therapy after your provider consultation, you receive a full refund of your first payment — no questions asked.
If your medication is lost or damaged in transit, we will resend at no additional charge. We stand behind every shipment.
Your health information is protected under HIPAA and will never be sold. Plain, discreet packaging on every delivery.
Real People. No Shame. All Confidence.
Medical weight loss isn’t a shortcut — it’s evidence-based care for a chronic condition. Paired with thoughtful eating, movement you enjoy, and ongoing provider support, GLP-1 therapy can be a turning point for people who’ve been trying on their own for years.
You deserve a care team that takes you seriously, treats your body with respect, and meets you wherever you are on the journey.
Obesity is a chronic medical condition — not a willpower failure. You wouldn’t hesitate to treat high blood pressure or diabetes. Treating weight is no different.
— The AvataCore Care Team
Healthcare without the long wait times or doctor denials.
Your medication is compounded by state-licensed sterile compounding pharmacies in the United States.
A licensed provider matches you to the right molecule, dose, and titration plan based on your intake.
Built on Tellescope, a SOC 2 telehealth platform. Your records and messages are secure.
Message your provider through your portal anytime. No phone tag, no waiting rooms.
One simple price. No hidden membership fees.
Connect with licensed providers in your state. Service available in 39+ U.S. states.
View all 50 states →Evidence-based information on weight-management conditions and GLP-1 therapy.
ICD-10 E66 · GLP-1 receptor agonist therapy for chronic weight management
Once-weekly injection or daily oral · GLP-1 receptor agonist
Once-weekly injection · Dual GLP-1 + GIP receptor agonist
Reviewed by OpenLoop Health clinicians
Start your weight management journey today. Our process is fast, simple, and backed by licensed providers.
Take the Quiz → It's FreeStarting at $149 · No membership fees · Cancel anytime